Ikarian Capital LLC 13D and 13G filings for Bellicum Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 6:00 pm Unchanged | 2023-12-31 | 13G | Bellicum Pharmaceuticals, Inc. BLCM | Ikarian Capital LLC | 448,101 4.600% | 0 (Unchanged) | Filing |
| 2023-02-14 11:02 am Sale | 2022-12-31 | 13G | Bellicum Pharmaceuticals, Inc. BLCM | Ikarian Capital LLC | 448,101 5.200% | -48,655 (-9.79%) | Filing |
| 2022-02-14 4:32 pm Sale | 2021-12-31 | 13G | Bellicum Pharmaceuticals, Inc. BLCM | Ikarian Capital LLC | 496,756 5.900% | -3,244 (-0.65%) | Filing |
| 2021-01-08 9:57 pm Purchase | 2020-12-24 | 13G | Bellicum Pharmaceuticals, Inc. BLCM | Ikarian Capital LLC | 500,000 9.900% | 500,000 (New Position) | Filing |